Combination effect of the Anti-PD-1 antibody and STAT3 inhibitor, STX-0119, using humanized MHC-dKO NOG mouse

被引：0
|
作者：
Ashizawa, Tadashi [1 ]
Iizuka, Akira [1 ]
Maruyama, Koji [2 ]
Asai, Akira [3 ]
Yamaguchi, Ken [1 ]
Akiyama, Yasuto [1 ]
机构：
[1] Shizuoka Canc Ctr, Res Inst, Dept Immunother, Nagaizumi, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Res Inst, Exp Anim Facil, Nagaizumi, Shizuoka, Japan
[3] Univ Shizuoka, Ctr Drug Discovery, Shizuoka, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2395
引用
收藏
页码：1032 / 1032
页数：1
相关论文
共 25 条
  • [21] IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors
    Tolcher, Anthony
    Hong, David
    Sullivan, Ryan
    Mier, James
    Shapiro, Geoffrey
    Pearlberg, Joseph
    Brail, Les
    Kharidia, Jahnavi
    Han, Lixin
    Ullmann, Claudio Dansky
    Stern, Howard M.
    Wolchok, Jedd D.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [22] Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways
    Kong, Qing
    Ma, Mengyu
    Zhang, Li
    Liu, Suqing
    He, Shan
    Wu, Jinfeng
    Liu, Baojun
    Dong, Jingcheng
    PHYTOMEDICINE, 2023, 110
  • [23] Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells
    Tsubasa Miyazaki
    Eiichi Ishikawa
    Masahide Matsuda
    Narushi Sugii
    Hedihiro Kohzuki
    Hiroyoshi Akutsu
    Noriaki Sakamoto
    Shingo Takano
    Akira Matsumura
    Brain Tumor Pathology, 2020, 37 : 41 - 49
  • [24] Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells
    Miyazaki, Tsubasa
    Ishikawa, Eiichi
    Matsuda, Masahide
    Sugii, Narushi
    Kohzuki, Hedihiro
    Akutsu, Hiroyoshi
    Sakamoto, Noriaki
    Takano, Shingo
    Matsumura, Akira
    BRAIN TUMOR PATHOLOGY, 2020, 37 (02) : 41 - 49
  • [25] A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
    Shankar, Sadhna
    Spira, Alexander I.
    Strauss, James
    Liu, Liqin
    La Motte-Mohs, Ross
    Wu, Tony
    Johnson, Syd
    Bonvini, Ezio
    Moore, Paul A.
    Wigginton, Jon M.
    Vasselli, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
123